Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2001
07/19/2001WO2001051051A2 AGENTS, SUCH AS NICOTINAMIDE OR cADPR FOR THE TREATMENT OF SKIN DISORDERS
07/19/2001WO2001051050A1 Novel substituted benzimidazole dosage forms and method of using same
07/19/2001WO2001051049A1 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
07/19/2001WO2001051048A1 Use of epigallocatechin-gallate for inhibiting angiogenesis
07/19/2001WO2001051047A1 Use of fumaric acid derivatives for treating mitochondrial diseases
07/19/2001WO2001051046A1 Airway alkalinization as therapy for airway diseases
07/19/2001WO2001051044A2 Substances for use in treating psoriasis
07/19/2001WO2001051043A2 Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
07/19/2001WO2001051042A2 Treatment of diabetic ulcers
07/19/2001WO2001051041A1 Osmotic device containing venlafaxine and an anti-psychotic agent
07/19/2001WO2001051040A1 Osmotic device containing alprazolam and an antipsychotic agent
07/19/2001WO2001051039A1 Osmotic device containing ranitidine and a prokinetic agent
07/19/2001WO2001051038A1 Osmotic device containing pseudoephedrine and an h1 antagonist
07/19/2001WO2001051037A1 Osmotic device containing diltiazem and an ace inhibitor or diuretic
07/19/2001WO2001051029A1 Itraconazole composition and production method
07/19/2001WO2001051028A2 Formulations and methods for administration of pharmacologically or biologically active compounds
07/19/2001WO2001051026A2 Instant granules and process for their formulation
07/19/2001WO2001051025A2 Formulations of active components in the form of a solid dispersion
07/19/2001WO2001051023A1 Use of orally administered dehydroepiandrosterone, precursors and derivatives thereof in order to improve the papery aspect of the skin
07/19/2001WO2001051022A1 Oral use of dehydroepiandrosterone and some of its derivatives as pigmentation regulators
07/19/2001WO2001051020A1 Antiperspirant compositions
07/19/2001WO2001051016A1 A method of treating an ailment by enhancing the effectiveness of the human immune system
07/19/2001WO2001051014A1 Pharmaceutical and cosmetic carrier or composition for topical application
07/19/2001WO2001051004A2 Anti-cancer agent containing naphthoquinone compound
07/19/2001WO2001051003A2 Use of lipid conjugates in the treatment of disease
07/19/2001WO2001050994A1 Topical medicated bioadhesive compositions and methods of use and preparation thereof
07/19/2001WO2001050987A2 Treatment of hepatitis c using hyperthermia
07/19/2001WO2001050881A2 Process and composition for controlling fecal hair excretion and trichobezoar formation
07/19/2001WO2001050873A1 Thickened oil compositions of edible oil
07/19/2001WO2001050860A1 Improved topical drug delivery composition and method
07/19/2001WO2001014414A3 Human abc2 transporter and uses thereof
07/19/2001WO2001013933A3 Agents for the enhanced oxygen delivery in mammals
07/19/2001WO2001012632A3 Phenanthroline-7-one derivatives and their therapeutic uses
07/19/2001WO2001012631A3 Ascididemin derivatives and their therapeutic applications
07/19/2001WO2001009076A3 Retinoids for the treatment of emphysema
07/19/2001WO2001005794A3 Method for making debromohymenialdisine and analogs thereof
07/19/2001WO2001005791A3 NEW PROCESS FOR THE PREPARATION OF N-(1,1-DIMETHYLETHYL)-4-[[5'-ETHOXY-4-cis-[2-(4-MORFOLINO)ETHOXY]-2'-OXOSPIRO[CYCLOHEXAN-1,3'-[H]INDOL]-1'(2'H)-yl]-SULFONYL]-3-METHOXYBENZAMIDE AND ITS SALTS
07/19/2001WO2001005762A3 Biphenyl derivatives, production thereof and use as mtp inhibitors
07/19/2001WO2001005758A3 Indoles and indazoles for the treatment of migraine
07/19/2001WO2001005408A8 Fat-binding polymers, optionally combined with lipase inhibitors
07/19/2001WO2001005392A3 Method for treating chronic pain using mek inhibitors
07/19/2001WO2001005391A3 Method for treating chronic pain using mek inhibitors
07/19/2001WO2001005386A3 Pharmaceutical composition useful for the treatment of tinnitus and hearing loss
07/19/2001WO2001005383A3 Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine
07/19/2001WO2001004297A3 Human proteins having hydrophobic domains and dnas encoding these proteins
07/19/2001WO2001004118A3 Quinuclidine derivatives and their use as muscarinic m3 receptor ligands
07/19/2001WO2001002424A3 Peptide boronic acid inhibitors of hepatitis c virus protease
07/19/2001WO2001001998A3 Treatment of endometriosis with antileukoprotease
07/19/2001WO2000076984A8 Novel compounds, their use and preparation
07/19/2001WO2000073296A3 3-heteroarylalkyl substituted gaba analogs
07/19/2001WO2000071703A3 Inhibition of histone deacetylase
07/19/2001WO2000071104A3 Use of bisphosphonic acids for treating angiogenesis
07/19/2001WO2000066105A3 Treatment of epilepsy with imino sugars
07/19/2001WO2000041474A3 Anti-cd3 immunotoxins and therapeutic uses therefor
07/19/2001WO2000040229A3 Synergistic tumorcidal response induced by histamine
07/19/2001WO2000032551A9 Sertraline hydrochloride polymorphs
07/19/2001WO1999060869A8 Sitostanol formulation with emulsifier to reduce cholesterol absorption
07/19/2001US20010008947 Administering derivative of 2-amino-4-phenyl-4-oxo-butyric acid which acts as kynureninase/kynurenine-3-hydroxylase enzyme inhibitor; neurodegenerative diseases
07/19/2001US20010008946 Therapeutic nucleosides
07/19/2001US20010008941 Treating osteoporosis; having no endometrial hyperplasia activity nor breast tumor proliferation activity
07/19/2001US20010008939 Also useful in treating viral infections; antiprotozoa (plasmodium) activity
07/19/2001US20010008936 Oligonucleotides having chiral phosphorus linkages
07/19/2001US20010008933 Novel disulfides and thiol compounds
07/19/2001US20010008905 Administering a compound such as hydroxyurea to deplete the intracellular pool of deoxyribonucleoside phosphate
07/19/2001US20010008904 Method for supplying bioavailable methionine to a cow
07/19/2001US20010008903 Dioxinoindole and thienobenzodioxin compounds which are ht3 receptor antagonists and are used to treat central nervous system disorders
07/19/2001US20010008902 Reduction of an unsaturated thiazolidine-2,4-dione derivative with metallic aluminum in a protic solvent; purity; antidiabetic agents
07/19/2001US20010008901 Nitrile derivatives that inhibit cathepsin K
07/19/2001US20010008900 Administration of pharmaceuticals
07/19/2001US20010008899 Administering (-) pantoprazole, or a pharmaceutically acceptable salt thereof, substantially free of its (+) stereoisomer; treatment of ulcers
07/19/2001US20010008898 Ether and amide compounds and preparation of thereof as antidiadetics.
07/19/2001US20010008897 Carrying out the resolution of (+/-) E-2-(3,4-dichlorocinnamyl)piperidine via the eutomeric diastereoisomeric salt with N-acetyl-L-phenylalanine, acylating, reducing with cyclopropanecarbonyl chloride
07/19/2001US20010008896 Treatment ofsexual disorders
07/19/2001US20010008894 Lipid-lowering quinazoline derivative
07/19/2001US20010008891 Pharmaceutical compositions comprising a xanthine and a catechin
07/19/2001US20010008890 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists
07/19/2001US20010008888 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
07/19/2001US20010008886 Treatment of corresponding nitrile derivative with hydrogen in the presence of hydrogenation catalyst; thrombolytic agents
07/19/2001US20010008885 Administering phosphocholine compound; leishmaniasis treatment
07/19/2001US20010008880 Thrombolytic agents and methods of treatment for thrombosis
07/19/2001US20010008772 Lipid, nucleic acid complex
07/19/2001US20010008757 Synthetic media for blood components
07/19/2001US20010008639 Reducing dosage; analgesics
07/19/2001US20010008638 Nutritional supplement comprising at least one prohormone and at least one anti-estrogen compound in a time-release dosage form
07/19/2001US20010008634 Bactericides, fungicides, insecticides
07/19/2001US20010008632 Aqueous medicament preparations for the production of propellent gas-free aerosols
07/19/2001US20010008629 Treatment of vascular events using lipid-modifying compositions
07/19/2001US20010008317 Fabrication of tissue products with additives by casting or molding using a mold formed by solid free-form methods
07/19/2001DE19961219A1 11beta-Phenylestratrien-Derivate mit Fluoralkylgruppen in der aromatischen Seitenkette, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen 11beta-Phenylestratrien derivatives with fluoroalkyl groups in the aromatic side chain, their preparation and pharmaceutical compositions containing them
07/19/2001DE10101543A1 Enhancing the antitumor activity of an amygdalin-containing material, especially loquat kernels, comprises roasting the material with far infrared radiation and fermenting it with microorganisms
07/19/2001DE10100772A1 New heterocyclic-substituted phenyl ether or N-phenyl amide compounds, are low-toxicity antidiabetic agents having insulin potentiating and hypoglycemic activity
07/19/2001DE10034494A1 Pharmazeutische Zusammensetzung gegen Ulkus und ihre Herstellung The pharmaceutical composition of anti-ulcer and their preparation
07/19/2001DE10001879A1 New benzoylguanidine derivatives are Na+/H+ exchange inhibitors useful for the treatment and prevention of e.g. ischemic disorders, infarction, arrhythmia, angina pectoris and stroke
07/19/2001DE10001785A1 Use of NK-1 receptor antagonists for treatment of restless legs syndrome
07/19/2001DE10001166A1 Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung Fused pyrrole compounds, pharmaceutical compositions containing them and their use
07/19/2001DE10001021A1 Pharmazeutische Zubereitung Pharmaceutical composition
07/19/2001DE10000807A1 Verfahren zur Behandlung eines kosmetischen Mittels durch Bestrahlung mit NIR-Strahlung, sowie dessen Verwendung A method for the treatment of a cosmetic product by means of irradiation with NIR radiation, and its use
07/19/2001DE10000792A1 Formulierungen von Wirkstoffen in Form einer festen Dispersion Formulations of active ingredients in the form of a solid dispersion
07/19/2001DE10000612A1 Aqueous active substance preparations, especially eye drops, nasal drops and nasal sprays, contain sodium chloride in place of preservatives
07/19/2001CA2401374A1 Method for the preparation of citalopram